Healthcare provider profile · identity verified

Michael A Flaningam, MD

Allopathic & Osteopathic Physicians|Internal Medicine · SILETZ, OR · NPI 1588775092

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Michael A Flaningam, MD received $76.70 in general payments during 2025 across 3 reported records.

Boston Scientific Corporation accounted for 39.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$76.70

3 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Boston Scientific Corporation Unresolved — no canonical attribution shown $30.5739.9%12025
Exact Sciences Corporation Unresolved — no canonical attribution shown $24.0031.3%12025
Indivior Inc. Unresolved — no canonical attribution shown $22.1328.9%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$76.703

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
WaveWriter Alpha Prime 16
Normalized: wavewriter alpha prime 16
Device Boston Scientific Corporation $30.57 1 2025
Source payment records
The Cologuard Plus Collection Kit
Normalized: the cologuard plus collection kit
Device Exact Sciences Corporation $24.00 1 2025
Source payment records
SUBLOCADE
Normalized: sublocade
Drug Indivior Inc. $22.13 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium15437
LisinoprilLisinopril10725
Levothyroxine SodiumLevothyroxine Sodium9821
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen9524
Amlodipine BesylateAmlodipine Besylate9023
Metoprolol SuccinateMetoprolol Succinate7319
GabapentinGabapentin6815
EliquisApixaban6612
Losartan PotassiumLosartan Potassium6511
HydrochlorothiazideHydrochlorothiazide6214
OmeprazoleOmeprazole5815
Pantoprazole SodiumPantoprazole Sodium56suppressed
Trazodone HclTrazodone Hcl55suppressed
Tamsulosin HclTamsulosin Hcl52suppressed
Metformin HclMetformin Hcl5013
Duloxetine HclDuloxetine Hcl47suppressed
Albuterol Sulfate HfaAlbuterol Sulfate4621
Metformin Hcl ErMetformin Hcl42suppressed
CarvedilolCarvedilol41suppressed
ClonazepamClonazepam40suppressed
BaclofenBaclofen39suppressed
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen36suppressed
Tramadol HclTramadol Hcl34suppressed
ValsartanValsartan34suppressed
Rosuvastatin CalciumRosuvastatin Calcium32suppressed
Escitalopram OxalateEscitalopram Oxalate29suppressed
Fluoxetine HclFluoxetine Hcl29suppressed
Metoprolol TartrateMetoprolol Tartrate28suppressed
AlprazolamAlprazolam27suppressed
IbuprofenIbuprofen27suppressed
MeloxicamMeloxicam26suppressed
Ondansetron OdtOndansetron26suppressed
Breo ElliptaFluticasone/Vilanterol24suppressed
Buprenorphine HclBuprenorphine Hcl24suppressed
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl24suppressed
Diclofenac SodiumDiclofenac Sodium23suppressed
TrulicityDulaglutide22suppressed
Oxybutynin Chloride ErOxybutynin Chloride21suppressed
Buspirone HclBuspirone Hcl20suppressed
Glipizide ErGlipizide20suppressed
JanuviaSitagliptin Phosphate20suppressed
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide20suppressed
Oxycodone HclOxycodone Hcl20suppressed
Zolpidem TartrateZolpidem Tartrate19suppressed
Hydroxyzine HclHydroxyzine Hcl18suppressed
SimvastatinSimvastatin18suppressed
SynthroidLevothyroxine Sodium18suppressed
Tizanidine HclTizanidine Hcl18suppressed
Amitriptyline HclAmitriptyline Hcl16suppressed
Cyclobenzaprine HclCyclobenzaprine Hcl15suppressed
FinasterideFinasteride15suppressed
Fluticasone PropionateFluticasone Propionate15suppressed
FurosemideFurosemide15suppressed
LamotrigineLamotrigine15suppressed
AtenololAtenolol14suppressed
MirtazapineMirtazapine14suppressed
PrednisonePrednisone1412
Propranolol HclPropranolol Hcl14suppressed
ClopidogrelClopidogrel Bisulfate13suppressed
Divalproex SodiumDivalproex Sodium13suppressed
Morphine SulfateMorphine Sulfate13suppressed
SpironolactoneSpironolactone13suppressed
AzithromycinAzithromycin1211
Ciprofloxacin HclCiprofloxacin Hcl12suppressed
EzetimibeEzetimibe12suppressed
HydrocortisoneHydrocortisone12suppressed
JardianceEmpagliflozin12suppressed
PregabalinPregabalin12suppressed
Sertraline HclSertraline Hcl12suppressed
Warfarin SodiumWarfarin Sodium12suppressed
Dicyclomine HclDicyclomine Hcl11suppressed
GemfibrozilGemfibrozil11suppressed
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11suppressed
NystatinNystatin11suppressed
OzempicSemaglutide11suppressed
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11suppressed
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid11suppressed
Valproic AcidValproic Acid11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $76.70 · 3 records Boston Scientific Corporation SUBLOCADE, The Cologuard Plus Collection Kit, WaveWriter Alpha Prime 16
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error